Richard A. Furie

1 month ago | pharmacytimes.com | Luke Halpern |Richard A. Furie

CommentaryVideoMarch 11, 2025Author(s):,In an interview with Pharmacy Times®, Richard Furie, MD, chief of the division of rheumatology at Northwell Health, explains how pharmacists play a critical role in educating and mitigating the risk of infections in patients with lupus nephritis being treated with obinutuzumab (Gazyva, Gazyvaro; Genentech).

1 month ago | pharmacytimes.com | Luke Halpern |Richard A. Furie

CommentaryVideoMarch 4, 2025Author(s):,Obinutuzumab is effective in reducing proteinuria and preserving kidney function in lupus nephritis, with consistent benefits across high-disease activity subgroups. In an interview with Pharmacy Times®, Richard Furie, MD, chief of the division of rheumatology at Northwell Health, discusses the observed efficacy of obinutuzumab (Gazyva, Gazyvaro; Genentech) in patients with lupus nephritis as seen in the phase 3 REGENCY clinical trial.

May 22, 2024 | lupus.bmj.com | Anca D. Askanase |Richard A. Furie |Maria Dall'Era |Andrew Bomback

Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Dec 20, 2023 | lupus.bmj.com | Laurent Arnaud |Richard A. Furie |Eric F. Morand |Martin Aringer

DiscussionSPOCS is a prospective, observational study designed to analyse clinical outcomes over time of a large, real-world cohort of patients with moderate-to-severe SLE. Overall, this study identified substantial clinical burden in a broadly representative group of patients with moderate-to-severe SLE in a real-world setting, including long disease duration and presence of organ damage in more than half of patients.

Oct 25, 2023 | futuremedicine.com | Richard A. Furie

This review describes the litifilimab (BIIB 059) development program to date for systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). Plasmacytoid dendritic cells (pDCs), major producers of type I interferons (IFN-I), play a key role in SLE pathogenesis. Litifilimab, a humanized monoclonal antibody, binds to BDCA2, a protein uniquely expressed on pDCs. The consequence of BDCA2 ligation is the inhibition of IFN-I as well as IFN-III, cytokine and chemokine production.